Myocarditis is an important cause of heart failure in young patients. Autoreactive, most often, infection-triggered CD4+ T cells were confirmed to be critical for myocarditis induction. Due to a defect in clonal deletion of heart-reactive CD4+ T cells in the thymus of mice and humans, significant numbers of heart-specific autoreactive CD4+ T cells circulate in the blood. Normally, regulatory T cells maintain peripheral tolerance and prevent spontaneous myocarditis development. In the presence of tissue damage and innate immune activation, however, activated self-antigen-loaded dendritic cells promote CD4+ effector T cell expansion and myocarditis. So far, a direct pathogenic role has been described for both activated Th17 and Th1 effector CD4+ T cell subsets, though Th1 effector T cell-derived interferon-gamma was shown to limit myocarditis severity and prevent transition to inflammatory dilated cardiomyopathy. Interestingly, recent observations point out that various CD4+ T cell subsets demonstrate high plasticity in maintaining immune homeostasis and modulating disease phenotypes in myocarditis. These subsets include Th1 and Th17 effector cells and regulatory T cells, despite the fact that there are still sparse and controversial data on the specific role of FOXP3-expressing Treg in myocarditis. Understanding the specific roles of these T cell populations at different stages of the disease progression might provide a key for the development of successful therapeutic strategies.

1. Introduction

Myocarditis represents a polymorphic, frequently infection-triggered, and immune-mediated inflammation of the heart muscle [1]. Most often, it resolves spontaneously, but in susceptible individuals, it can progress to a chronic stage, which finally results in pathological cardiac remodelling. Pathological remodelling includes tissue fibrosis, hypertrophy, and apoptosis of cardiomyocytes and results in a phenotype of dilated heart chambers with impaired contractility (inflammatory dilated cardiomyopathy (iDCM)). Patients with iDCM develop heart failure with high mortality [2]. In children, myocarditis leads to cardiomyopathy in 46% of affected individuals [3], and up to 20% of sudden death cases in young adults have been reported to be due to myocarditis [4]. Diagnostic gold standard is myocardial biopsy, despite a lack of sensitivity, mainly due to sampling error [2, 5]. Nevertheless, appropriate histological, immunohistochemical, and molecular biological workup of sufficient numbers of heart biopsies greatly improved diagnostic accuracy and allows meanwhile not only a morphological classification but also detection of replicating viral genomes in the heart [6, 7].

Viral infections are the most frequent cause of myocarditis along with some bacteria, and protozoa. Moreover, toxins, vaccines, and several drugs, as well as systemic autoimmune diseases, can also trigger heart-specific autoimmunity and inflammation [8]. Following tissue damage of any cause, the release of cardiac self-antigens and activation of scavenging self-antigen-presenting dendritic cells in draining lymph nodes may result in a breakdown of heart-specific tolerance triggering production of heart-specific autoantibodies, autoreactive CD4+ T cell expansion, and autoimmunity [9, 10]. Various intracellular cardiac peptides, surface receptors, and mitochondrial antigens had been reported as markers of cardiac injury [11], but not all of them are heart specific or promote autoimmunity. Autoantibodies to both cardiac troponin T and I had been detected in sera of mice and men, but only immunization with troponin I led to myocarditis in mice [12, 13]. Autoantibodies to beta1-adrenoceptors
had been shown to promote dilated cardiomyopathy in rodents [14, 15] and are associated with adverse outcome in patients with dilated cardiomyopathy [16, 17] or Chagas heart disease [18]. Patients with dilated cardiomyopathy also demonstrate increased serum levels of autoantibodies to M(2) muscarinic acetylcholine receptor. In mice, adoptive transfer of M(2) muscarinic acetylcholine receptor-specific splenocytes induces cardiomyocarditis, with T cell infiltrations in the heart and a dilated cardiomyopathy-like phenotype [19]. Epitopes of the alpha-myosin heavy chain (α-MyHC) peptide are heart specific, highly immunogenic in various animal models, and associated with autoantibodies and T cell-mediated myocarditis both in mice and humans [20–23].

CD4+ T cells were defined as main drivers of heart-specific autoimmunity in myocarditis [24–27]. Expansion of heart-specific effector CD4+ T cells is facilitated in humans and mice due to a high frequency of circulating naïve α-MyHC-specific CD4+ T cells. The high frequency of α-MyHC-specific CD4+ T cells is a result of defective negative selection in the thymus. In fact, transcripts of Myh6, the gene encoding murine α-isofrom of myosin heavy chain, are absent in mouse medullary thymic epithelial cells. Humans also do not express α-MyHC in mTECs. Accordingly, patients with inflammatory cardiomyopathy demonstrate increased T cell responses against α-MyHC [28]. Taken together, a natural gap in negative selection of α-MyHC-specific CD4+ T cells can explain susceptibility to heart-specific autoimmunity in the context of tissue damage, self-antigen release, or exposure to pathogen-derived molecules mimicking cardiac proteins [29].

Effector CD4+ T cells (Teff) were reported to be critical for myocarditis development in patients and animal models [24, 30]. Starting from their naïve form, CD4+ T cells differentiate into either mature effector or regulatory cell populations with distinct functions [31, 32]. Aside from CD4+ T cell subsets including regulatory T cells (Treg), several other cell types can exert a regulatory suppressive function in myocarditis development. Such cells include bone marrow-derived progenitor cells, CD8+ T cells, monocytes/alternatively activated macrophages, or dendritic cells [33–37]. Regulatory T cells, expressing forkhead box P3T (FOXP3), suppress effector cells and maintain immune homeostasis and tolerance in various autoimmune disease models, but their role in myocarditis is still debatable [38–41]. Importantly, there is functional polymorphism and high plasticity in all the different T cell subpopulations [42, 43]. In fact, the regulatory role of the different T cell subtypes in myocarditis highly depends on the stage of disease and on a complex and not yet understood interaction between different inflammatory heart infiltrating and heart resident cell types. IFN-γ-producing Th1 effector T cells can convert to suppressor cells [44]. Vice versa, Treg are also able to produce proinflammatory cytokines under certain conditions [45]. In fact, dual IL-17-producing FOXP3+ regulatory T cells may play a critical role in controlling inflammatory balance in humans [46]. Whether these observations are also valid in the context of cardiac inflammatory diseases is not known, however. In this review, we will focus specifically on the regulatory role of different CD4+ T cell subtypes in general in the context of myocarditis and its progression to inflammatory dilated cardiomyopathy. Our current knowledge largely bases on mouse and rat models of viral and experimental myocarditis, as well as from observational studies on patients with myocarditis or inflammatory dilated cardiomyopathy.

2. CD4+ T Cells as Critical Mediators of Heart-Specific Autoimmunity

Autoimmune mechanisms play an important role in myocarditis development and in its progression to inflammatory dilated cardiomyopathy. In patients and mice with myocarditis, heart-specific autoantibodies can be detected [5, 11]. The role of these autoantibodies for disease induction and progression, however, is still largely speculative [47]. In patients with acute myocarditis, biopsies demonstrate accumulation of T cells and macrophages, as well as other inflammatory cells in close contact to injured cardiomyocytes [48, 49]. Many studies, most of them based on mouse models, indicate an exclusive role for CD4+ T cells in myocarditis development and progression. Susceptible mouse strains develop myocarditis after viral, especially coxsackievirus B3 (CVB3), infection [50], as well as upon injections of α-MyHC peptide together with complete Freund’s adjuvant [51] or activated in vitro α-MyHC-loaded bone marrow-derived dendritic cells [9]. Transgenic mice carrying a CD4+ T cell receptor specific to cardiac myosin spontaneously develop myocarditis progressing to lethal-dilated cardiomyopathy [52]. In all of these mouse models, myocarditis is associated with a marked α-MyHC-reactive effector T helper (Th) cell response. These cells are directly pathogenic, because adoptive transfer of heart-specific CD4+ T cells can induce myocarditis in irradiated recipients, SCID, or Rag2-/- mice [24].

3. T Cell Maturation: Where Is the Breach?

Random recombination in the generation of the diversity of the T cell receptor (TCR) repertoire is an important evolutionary mechanism allowing T cells to specifically recognize and eliminate a large variety of foreign antigens. However, it also harbours potential danger of generating self-reactive clones. Under normal healthy conditions, there are two distinct stages of central and peripheral tolerance, which prevent autoimmunity during the development and activation of T cells. Central tolerance is based on clonal deletion and clonal diversion and is responsible for extracting self-reactive lymphocytes in the thymus [53]. Positively selected for their ability to recognise MHC complexes, thymocytes migrate to the thymic medulla and undergo a process of negative selection. Bearing strongly self-reactive TCRs, cells respond to self-peptide-MHC complexes on medullary thymic epithelial cells and receive apoptotic signals. The autoimmune regulator (AIRE) protein has been shown to play a major role in expression of self-tissue-specific epitopes in these complexes [54]. Humans and mice with compromised or absent AIRE suffer from variable severe autoimmunity in almost all their organs [55]. Just recently, Fez2, another transcription factor, was introduced to directly
regulate various tissue-restricted antigen genes in mTECs independent of AIRE [56]. The key mechanisms however are still largely unknown. Meaningfully, and as mentioned above, the expression of α-MyHC is missing in both, humans and mouse mTECs, leading to a defect in negative selection of alpha-myosin heavy chain-specific CD4⁺ T cells in the thymus putting them at risk for autoimmune myocarditis development in the presence of self-antigen release and innate immune activation (Figure 1).

CD45⁺MHCI⁺ bone marrow-derived antigen-presenting cells (APC) constantly process heart-specific epitopes in the heart [57]. This observation was made in many rodent strains, including some, which are not susceptible to viral or immune-mediated myocarditis. Obviously, presentation of cardiac antigens alone is not sufficient for activation and expansion of T eff and myocarditis development. Activation of CD4⁺ T cells requires not only interaction with a cognate antigen expressed on the MHC class II molecule but also costimulatory signals, such as those mediated by CD28 ligation [58]. In the absence of a local inflammatory milieu, DCs do not express sufficient amounts of costimulatory B7 family molecules and are supposed to play a tolerogenic role. CD4⁺ T cells interacting with MHC peptide without costimulatory signal undergo energy, repression of TCR signalling, and IL-2 production [59].

Surface APC molecules programmed death 1 receptor (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) play an important role in T cell anergy. Deficiency in PD-1 or CTLA-4 leads to impaired peripheral tolerance and enhanced T cell activation [60]. In fact, mice deficient for CTLA-4, PD-1, or its ligand demonstrate elevated numbers of effector T cells and develop severe autoimmune myocarditis and DCM [61–64]. By maintaining signalling through these molecules, DCs mediate the peripheral conversion of naive T cells to Treg. Acute inflammatory processes in the heart, on the other hand, result in upregulation of MHC II peptide complexes as well as costimulatory molecules on the surface of DCs and enhance migration of DC to the draining lymph nodes, where they interact with circulating T cells. This leads to a breakdown of peripheral tolerance and differentiation of naïve T cells into an effector phenotype (Figure 1).

4. The Role of Treg in Myocarditis

Since first identified and described as suppressive "regulatory" T cells [65], Treg were intensively studied [66]. Regulatory CD4⁺CD25⁺ T cells represent a specific T cell population responsible for immune homeostasis and tolerance. Their frequencies in the circulation can widely differ depending on the conditions or stage of disease [67]. Treg express FOXP3 transcription factor, which is essential for active suppression of autoimmunity [68]. As other T cells, Treg mainly develop in the thymus, but can also develop in the periphery. Treg suppress autoimmune T eff populations as well as APCs involved in priming and activation via different cell-cell contact-dependent and contact-independent mechanisms. Treg produce inhibitory cytokines such as transforming growth factor beta (TGF-β) and IL-10 or express surface molecules with immunosuppressive properties such as CTLA-4 or glucocorticoid-induced tumor necrosis factor receptor (GITR) modulating immune processes [69–71]. Expansion of regulatory cells is an important mechanism to control autoimmunity. In mouse and rat models of experimental autoimmune myocarditis, EAM numbers of Treg conversely correlated with disease severity. Moreover, the proliferation capacity and inhibitory activity of Treg increased in animals immunized for EAM induction [72, 73]. Adoptive transfer of CD4⁺ T cells depleted from highly efficient glucocorticoid-induced TNFR family-related gene/protein-expressing Treg resulted in more severe myocarditis in T cell-deficient BALB/c nude mice [74]. Furthermore, adoptive transfer of Treg protected mice from CVB3-induced myocarditis [75] and from progression to cardiomyopathy, if injected after clearance of the acute virus infection [76, 77]. Differences in numbers of circulating Treg explain variations in the susceptibility of different mouse strains to EAM. Comparison of A.SW and B10.S mouse strains sharing the same MHC haplotype showed that development of severe disease in A.SW mice correlated with a lower relative frequency of Treg among the total CD4⁺ T cell count, compared to resistant B10.S animals [26]. Moreover, gender differences in myocarditis development were linked to differences in circulating Treg. Mice with increased estradiol levels, for example, increased numbers of Treg upon immunization and are less susceptible to CVB3-induced myocarditis [78]. Monocytic myeloid-derived cells from female but not male mice promoted expansion of CD4⁺IL-10⁺ Treg [36]. Furthermore, IL-10 producing Treg transferred to immunized Lewis rats efficiently suppressed myocarditis induction [79]. A decrease in IL-10 production and Treg numbers was also observed in α-MyHC/CFA-immunized mice after endothelin receptor blockade and resulted in exacerbated EAM [80]. IL-10 efficiently drives the generation of Treg [81] while its immunosuppressive effect includes decreasing MHC II complexes and B7 family costimulatory molecules on the APC surface [82–84]. IL-37 mediated activation of Treg, and IL-10 production downregulates the expression of Th17-related cytokines IL-6 and IL-17 and ameliorates CVB3-induced viral myocarditis [85]. IL-35, on the other hand, was shown not only to have suppressive activities [86] but also to convert naïve T cells into a regulatory phenotype [87].

TGF-β directly suppresses self-reactive cells, as shown in models of experimental mouse colitis [88] and encephalitis [89], and protects mice against coxsackievirus-induced myocarditis [75]. Moreover, TGF-β launches a paracrine positive feedback loop converting naïve into regulatory CD4⁺ T cells [90]. TGF-β, however, was shown to promote disease and adverse cardiac remodelling during later stages of myocarditis: TGF-β-mediated Wnt secretion promoted myofibroblast differentiation and myocardial fibrosis in EAM [91], while treatments targeting TGF-β prevented fibrosis and heart failure [92–94].

Human CTLA4 haploinsufficiency results in serious dysregulation in T and B lymphocyte homeostasis and specifically affects FOXP3⁺ Treg cells [95]. CTLA-4 as a high-affinity receptor interacts with CD80/CD86 signalling
[96], causes elimination of these molecules via transendo-
cytosis [97], and suppresses IL-2—a major T cell survival and expansion factor [98–100]. Adenovirus vector-
mediated CTLA4Ig gene transfer in mice with EAM leads
to downregulation of CTLA-4 and B7-2 proteins but
upregulation of Treg, expression of FOXP3 and TGF-β
mRNA, and alleviation of myocarditis [73]. Patients with
Chagas heart disease demonstrate increased frequencies
of suppressive IL-6⁺, IFN-γ⁺, TNF-α⁺, and CTLA-4⁺ Treg
cells but a rather small FOXP3⁺CTLA-4⁺ Treg cell
population [101, 102]. Reduction of CTLA-4 levels in
CD4⁺ T cells following disruption of T cell Ig mucin
signalling during the innate immune response results in
decreased Treg populations and increased inflammation
in the heart [103]. A direct cytolytic effect of Treg is
due to a granzyme B-dependent, perforin-independent
mechanism [104] which allows them to eliminate target
effector cells.

Interestingly, some observations demonstrate that early
activation of Treg might be associated with exacerbation of

**Figure 1:** Role of CD4⁺ T cells in myocarditis. Break of central tolerance: CD4⁺ T cells undergo maturation and selection in the thymus. Due to a defect in negative selection, α-MyHC-specific CD4⁺ T cells do not undergo anergy or apoptosis and are released to the periphery. Break of peripheral tolerance: Inflammation results in activation of α-MyHC-loaded DCs which upregulate MHC II-peptide complexes as well as costimulatory molecules on the surface and migrate to the draining lymph nodes, where they interact with circulating T cells. Activated through the TCR meeting cognate peptide and upon costimulation with CD28, naive heart-specific T cells differentiate to effector T cells entering the heart.
CVB3-induced myocarditis [105]. Other viral myocarditis models, however, demonstrate the ability of Treg to decrease virus-induced inflammation and to limit tissue damage associated with viral infection [106]. Thrombospondin-2, for example, protected against cardiac dysfunction in acute CVB3-induced viral myocarditis via activation of anti-inflammatory Treg [107]. Valproic acid was suggested as a promising drug in the therapy of viral myocarditis increasing the percentage of Treg cells and decreasing the percentage of splenic Th17 [108]. Moreover, an approach modulating Th17/Treg immune responses by inhibition of microRNA-155 resulted in a simultaneous decrease of both Th17 and Th17/Treg immune responses by inhibition of microRNA-34a in splenic Th17 [108]. Moreover, an approach modulating the percentage of Treg cells and decreasing the percentage of CVB3-induced viral myocarditis via activation of anti-inflammatory Treg cells in myocarditis induction is well described [10], although mechanisms remain still poorly understood. It was established that IL-17-producing Th17 cells play a major role in initiation and development of myocarditis [122]. Though both Th1 and Th17 cooperate in disease progression and transition to iDCM [52], it was claimed that IFN-γ and IL-17 have antagonistic functions in myocarditis and inflammatory cardiomyopathy. Immunosuppressive strategies are beneficial for some patients with iDCM and myocarditis, without evidence on actively replicating viruses in heart biopsies [2]. Thus, elimination of Th17 and their proinflammatory cytokines appears as a promising therapeutic strategy. Nevertheless, some contradictory findings have also been reported. It was shown recently that T-cells—Th1, Th17, and Th17 in particular—possess great capacity to plasticity and are able to change their function and phenotype depending on the local milieu in tissue and lymph nodes. CD4+ T cells often coexpress more than one specific cytokine [123]. Th17 cells, for example, often produce IL-17 and IFN-γ [124]. In fact, in a model of experimental autoimmune encephalomyelitis (EAE), it was shown that IL-23-induced IL-17-producing Th17 demonstrated plasticity, that is, the capacity to change their cytokine production profiles in different inflammatory settings. Using a reporter mouse strain designed to fate map cells that have activated IL-17A, Hirota et al. demonstrated that former Th17 cells produced almost exclusively IFN-γ and other proinflammatory cytokines in the spinal cord [125]. Another study of effector cell plasticity underlines the nonstability of the IL-17+/IFN-γ+ population and further differentiation to IL-17 or IFN-γ single-producing cells [126]. Both Th1 and Th17 undergo active expansion in autoimmune myocarditis, and the balance between these populations may strongly influence disease phenotype and outcome. It was observed that α-MyHC/CFA-immunized IFN-γ- and IFN-γR-deficient mice develop more severe and persistent myocarditis [127, 128], suggesting a protective regulatory role of IFN-γ in this disease model. While in wild-type mice inflammatory infiltrates largely subside within few days after the peak of disease, IFN-γ-R-deficient show ongoing expansion of autoreactive CD4+ T cells, persistent inflammatory infiltrates, and enlarged, functionally impaired hearts with impaired nitric oxide production [128]. It was then confirmed that IFN-γ signalling is crucial for NO production by inducible nitric oxide synthase (NOS) 2 in tumor necrosis factor-α- and NOS2-producing dendritic cells, which limit expansion of Th17 and cardiac inflammation [33]. In fact, the progressive disease course in IFN-γ-R-deficient mice was associated with enhanced IL-17 release from heart-infiltrating Th17 cells. The EAM model also demonstrated that IL-17 recruits CD11b+ monocytes confining disease progression in an IFN-γ-dependent manner [129]. Moreover, IFN-γ signalling was crucial for prevention of EAM by vaccination of mice with FMS-like tyrosine kinase 3 ligand pretreated, α-MyHC-loaded splenic CD8+ DCs. In this experimental approach, DC vaccination enhanced the Th1 response, which was considered to negatively regulate expansion of Th17 effector cell expansion [130]. In line with these findings, IFN-γ-deficient mice also showed severely impaired systolic and diastolic functions and heart failure [131]. In a mouse model of adenovirus 1 infection-mediated myocarditis, depletion of IFN-γ during the acute phase of disease did not affect viral replication, but reduced cardiac inflammation protecting from remodeling and hypertrophy [132]. High IFN-γ levels correlated with cardiac damage and dysfunction in an autoimmune myocarditis model enhanced by purinergic receptor P2X7 deficiency [133]. Mice

5. Regulatory Role of CD4+ T Effector Cells in Progression of Myocarditis to iDCM

Several observations support a role for CD4+ T cells as major drivers of autoimmune myocarditis development [72, 121]. During myocarditis induction, various inflammatory cell subsets infiltrate the heart and produce proinflammatory cytokines, which create an amplification loop enhancing disease progression [72]. The crucial role of self-reactive CD4+ T cells in myocarditis induction is well described [10], although mechanisms remain still poorly understood. It is established that IL-17-producing Th17 cells play a major role in initiation and development of myocarditis [122]. Though both Th1 and Th17 cooperate in disease progression and transition to iDCM [52], it was claimed that IFN-γ and IL-17 have antagonistic functions in myocarditis and inflammatory
lacking Regnase-1 and Roquin, RNA-binding proteins that are essential for degradation of inflammatory mRNAs, demonstrated increased expression of IFN-γ, but not IL-17, and suffered from severe inflammation and fibrosis in their hearts [134]. Dampening IFN-γ overexpression by Ebi3, a compartment of IL-27, prevented T. cruzi-induced myocarditis in mice [135]. Thus, although some studies indicate a protective role of IFN-γ as a negative regulator of Teff responses, the same cytokine can also contribute to myocardial inflammation and pathological remodeling.

Recent findings indeed suggest that Teff may play a dual role in myocarditis progression. IL-17 increases myocarditis severity during the acute inflammatory stage [31, 136]. In contrast, it was observed in a T. cruzi infection model that anti-mouse IL-17 antibody increased myocarditis severity and mortality [137]. IL-17 signalling via IL-17RA mediated recruitment of IL-10-producing neutrophils, which in turn protect from the development of fatal cardiomyopathy in this model [138]. In line with these findings, it has been shown that in human Chagas disease patients, low frequencies of IL-17-producing T cells correlate with more severe symptoms and cardiac dysfunction [139]. A link between Th17 and Treg has also been shown in a model of viral myocarditis. Neutralization of IL-17 in mice, with an anti-mouse IL-17 Ab, resulted in a decrease in Treg counts and T cells with cytokines (TGF-β, IL-10) [140]. In patients with inflammatory dilated cardiomyopathy, IL-17 seems essential for the transition of myocarditis to iDCM, but serum levels of IL-17 normalize within one year after the diagnosis, whereas cytokines like IL-6 and TGF-β remain permanently increased in these patients [141, 142]. Moreover, low serum concentrations of IL-17 were associated with a worse prognosis for patients with acute myocardial infarction [143].

Mice immunized with pcDNA3-hM2, a DNA plasmid carrying the entire muscarinic acetylcholine receptor M2 (M2AChR) cDNA sequence, develop anti-M2AChR-associated DCM mimicking the human cardiomyopathy phenotype. In this DCM model, mice lacking P2×7 receptors produced lower amounts of IL-17 and higher amounts of IFN-γ and showed more severe cardiac dysfunction at later stages of disease [133]. Finally, it was shown that mice lacking both cytokines, IL-17 and IFN-γ, simultaneously developed rapidly fatal EAM [144]. In line with these findings, unpublished observations from a group also point to a different role of IFN-γ and IL-17 in the development of cardiac fibrosis following acute myocarditis.

Further studies in animal models, as well as in human tissue samples, will be required to fully understand the specific role of all different CD4+ T cell subsets in myocarditis. Nevertheless, these mechanistic insights are a critical requirement for the development of novel therapeutic concepts and vaccination strategies.

### Abbreviations

- AIRE: Autoimmune regulator
- APC: Antigen-presenting cells
- cDNA: Complementary DNA
- CFA: Complete Freund’s adjuvant
- CTLA-4: Cytotoxic T lymphocyte antigen-4
- CVB3: Coxsackievirus B3
- DC: Dendritic cells
- EAE: Experimental autoimmune encephalomyelitis
- EAM: Experimental autoimmune myocarditis
- FOXP3: Forkhead box P3
- GITR: Glucocorticoid-induced tumor necrosis factor receptor
- (i) DCM: (Inflammatory) dilated cardiomyopathy
- IFN-γ: Interferon-γ
- IL: Interleukin
- ILR: Interleukin receptor
- M2AChR: Muscarinic acetylcholine receptor M2
- MHC II: Major histocompatibility complex II
- mTEC: Medullary thymic epithelial cells
- α-MyHC: Alpha-myosin heavy chain
- NO: Nitric oxide
- NOS: Nitric oxide synthase
- PD-1: Programmed death 1 receptor
- TCR: T cell receptor
- Teff: Effector T cells
- TGF-β: Transforming growth factor beta
- Th: T helper cells
- TNF: Tumor necrosis factor
- Treg: Regulatory T cells.

### Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

### References

1. A. L. Caforio, S. Pankuweit, E. Arbustini et al., “Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases,” European Heart Journal, vol. 34, no. 33, pp. 2636–2648, 2013.
2. S. Heymans, U. Eriksson, J. Lehtonen, and L. T. Cooper Jr, “The quest for new approaches in myocarditis and inflammatory cardiomyopathy,” Journal of the American College of Cardiology, vol. 68, no. 21, pp. 2348–2364, 2016.
3. J. A. Towbin, A. M. Lowe, S. D. Colan et al., “Incidence, causes, and outcomes of dilated cardiomyopathy in children,” JAMA, vol. 296, no. 15, pp. 1867–1876, 2006.
[4] L. T. Cooper Jr., “Myocarditis,” The New England Journal of Medicine, vol. 360, no. 15, pp. 1526–1538, 2009.

[5] N. Neu, K. W. Beisel, M. D. Traystman, N. R. Rose, and S. W. Craig, “Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis,” The Journal of Immunology, vol. 138, no. 8, pp. 2488–2492, 1987.

[6] H. T. Aretz, M. E. Billingham, W. D. Edwards et al., “Myocarditis. A histopathologic definition and classification,” The American Journal of Cardiovascular Pathology, vol. 1, no. 1, pp. 3–14, 1987.

[7] A. L. Caforio, F. Calbrese, A. Angelini et al., “A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis,” European Heart Journal, vol. 28, no. 11, pp. 1326–1333, 2007.

[8] H. Mahrholdt, A. Wagner, C. C. Deluigi et al., “Presentation, patterns of myocardial damage, and clinical course of viral myocarditis,” Circulation, vol. 114, no. 15, pp. 1581–1590, 2006.

[9] U. Eriksson, R. Ricci, L. Hunziker et al., “Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity,” Nature Medicine, vol. 9, no. 12, pp. 1484–1490, 2003.

[10] W. Bracamonte-Baran and D. Cihakova, “Cardiac autoimmunity: myocarditis,” Advances in Experimental Medicine and Biology, vol. 1003, pp. 187–221, 2006.

[11] A. L. Caforio, F. Tona, S. Bottaro et al., “Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy,” Autoimmunity, vol. 41, no. 1, pp. 35–45, 2008.

[12] T. Okazaki, Y. Tanaka, R. Nishio et al., “Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice,” Nature Medicine, vol. 9, no. 12, pp. 1477–1483, 2003.

[13] S. Goser, M. Andrassy, S. J. Buss et al., “Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium,” Circulation, vol. 114, no. 16, pp. 1693–1702, 2006.

[14] N. J. Freedman and R. J. Lefkowitz, “Anti-β1-adrenergic receptor antibodies and heart failure: causation, not just correlation,” The Journal of Clinical Investigation, vol. 113, no. 10, pp. 1379–1382, 2004.

[15] R. Jahn, V. Boivin, L. Hein et al., “Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy,” The Journal of Clinical Investigation, vol. 113, no. 10, pp. 1419–1429, 2004.

[16] S. Stöhr, V. Boivin, R. Horf et al., “Stimulating autoantibodies directed against the cardiac β1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy,” American Heart Journal, vol. 152, no. 4, pp. 697–704, 2006.

[17] M. Dandel, G. Wallukat, A. Englert, H. B. Lehmkuhl, C. Knoalla, and R. Hetzer, “Long-term benefits of immunoabsorption in β1-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy,” European Journal of Heart Failure, vol. 14, no. 12, pp. 1374–1388, 2012.

[18] V. Labovsky, C. R. Smulski, K. Gómez, G. Levy, and M. J. Levin, “Anti-β1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease,” Clinical & Experimental Immunology, vol. 148, no. 3, pp. 440–449, 2007.

[19] A. Yoshizawa, S. Nagai, Y. Baba et al., “Autoimmunity against M1 muscarinic acetylcholine receptor induces myocarditis and leads to a dilated cardiomyopathy-like phenotype,” European Journal of Immunology, vol. 42, no. 5, pp. 1152–1163, 2012.

[20] Z. Wang, Y. Liao, J. Dong, S. Li, J. Wang, and M. L. Fu, “Clinical significance and pathogenic role of anti-cardiac myosin autoantibody in dilated cardiomyopathy,” Chinese Medical Journal, vol. 116, no. 4, pp. 499–502, 2003.

[21] K. E. Simpson, M. W. Cunningham, C. K. Lee et al., “Autoimmunity against the heart and cardiac myosin in children with myocarditis,” Journal of Cardiac Failure, vol. 22, no. 7, pp. 520–528, 2016.

[22] A. L. Caforio, M. Grazzini, J. M. Mann et al., “Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy,” Circulation, vol. 85, no. 5, pp. 1734–1742, 1992.

[23] J. H. Goldman, P. J. Keeling, R. S. Warraca et al., “Autoimmunity to alpha myosin in a subset of patients with idiopathic dilated cardiomyopathy,” British Heart Journal, vol. 74, no. 6, pp. 598–603, 1995.

[24] S. C. Smith and P. M. Allen, “Myosin-induced acute myocarditis is a T cell-mediated disease,” The Journal of Immunology, vol. 147, no. 7, pp. 2141–7, 1991.

[25] J. M. Penninger, C. Pummerer, P. Liu, N. Neu, and K. Bachmaier, “Cellular and molecular mechanisms of murine autoimmune myocarditis,” APMIS, vol. 105, no. 1-6, pp. 1–13, 1997.

[26] P. Chen, G. C. Baldeviano, D. L. Ligons et al., “Susceptibility to autoimmune myocarditis is associated with intrinsic differences in CD4+ T cells,” Clinical & Experimental Immunology, vol. 169, no. 2, pp. 79–88, 2012.

[27] K. Van der Borght, C. L. Scott, V. Nindl et al., “Myocardial infarction primes autoreactive T cells through activation of dendritic cells,” Cell Reports, vol. 18, no. 12, pp. 3005–3017, 2017.

[28] H. J. Lv, “Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans,” The Journal of Clinical Investigation, vol. 121, no. 4, pp. 1561–1573, 2011.

[29] U. Nussinovitch and Y. Shoenfeld, “The diagnostic and clinical significance of anti-muscarinic receptor autoantibodies,” Clinical Reviews in Allergy and Immunology, vol. 42, no. 3, pp. 298–308, 2012.

[30] B. P. Amoah, H. Yang, P. Zhang, Z. Su, and H. Xu, “Immunopathogenesis of myocarditis: the interplay between cardiac fibroblast cells, dendritic cells, macrophages and CD4+ T cells,” Scandinavian Journal of Immunology, vol. 82, no. 1, pp. 1–9, 2015.

[31] I. Sonderegger, T. A. Röhn, M. . O. Kurrer et al., “Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis,” European Journal of Immunology, vol. 36, no. 11, pp. 2849–2856, 2006.

[32] Y. Matsumoto, Y. Jee, and M. Sugisaki, “Successful TCR-based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR,” The Journal of Immunology, vol. 164, no. 4, pp. 2248–2254, 2000.

[33] G. Kania, S. Siegert, S. Behnke et al., “Innate signaling promotes formation of regulatory nitric oxide-producing dendritic cells limiting T-cell expansion in experimental
autoimmune myocarditis,” *Circulation*, vol. 127, no. 23, pp. 2285–2294, 2013.

[34] G. Kania, P. Błyszczuk, A. Valaperti et al., “Prominin-1/CD133+ bone marrow-derived heart-resident cells suppress experimental autoimmune myocarditis,” *Cardiovascular Research*, vol. 80, no. 2, pp. 236–245, 2008.

[35] V. Taneja and C. S. David, “Spontaneous autoimmune myocarditis and cardiomyopathy in HLA-DQ8:NOD:Ab2 transgenic mice,” *Journal of Autoimmunity*, vol. 33, no. 3-4, pp. 260–269, 2009.

[36] N. Su, Y. Yue, and S. Xiong, “Monocyteic myeloid-derived suppressor cells from females, but not males, alleviate CVB3-induced myocarditis by increasing regulatory and CD4+IL-10+ T cells,” *Scientific Reports*, vol. 6, no. 1, p. 22658, 2016.

[37] S. Frisano-Kiss, M. J. Coronado, J. A. Frisano et al., “Gonadectomy of male BALB/c mice increases Tim-3+ alternatively activated M2 macrophages, Tim-3+ T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis,” *Brain, Behavior, and Immunity*, vol. 23, no. 5, pp. 649–657, 2009.

[38] S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, “Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases,” *The Journal of Immunology*, vol. 155, no. 3, pp. 1151–1164, 1995.

[39] C. L. Bennett, J. Christie, F. Ramsdell et al., “The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3,” *Nature Genetics*, vol. 27, no. 1, pp. 20–1, 2001.

[40] J. M. Kim, J. P. Rasmussen, and A. Y. Rudensky, “Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice,” *Nature Immunology*, vol. 8, no. 2, pp. 191–197, 2007.

[41] P. Pandiyan, L. Zheng, S. Ishihara, J. Reed, and M. J. Lenardo, “CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells,” *Nature Immunology*, vol. 8, no. 12, pp. 1353–1362, 2007.

[42] M. Kleinewietfeld and D. A. Hafler, “The plasticity of human Treg and Th17 cells and its role in autoimmunity,” *Seminars in Immunology*, vol. 25, no. 4, pp. 305–312, 2013.

[43] L. Cosmi, L. Maggi, V. Santarlasci, F. Liotta, and F. Annunziato, “T helper cells plasticity in inflammation,” *Cytometry Part A*, vol. 85, no. 1, pp. 36–42, 2014.

[44] B. M. Hall, “T cells: soldiers and spies—the surveillance and control of effector T cells by regulatory T cells,” *Clinical Journal of the American Society of Nephrology*, vol. 10, no. 11, pp. 2050–2064, 2015.

[45] G. L. Cvetanovich and D. A. Hafler, “Human regulatory T cells in autoimmune diseases,” *Current Opinion in Immunology*, vol. 22, no. 6, pp. 753–760, 2010.

[46] K. S. Voo, Y. H. Wang, F. R. Santori et al., “Identification of IL-17-producing FOXP3+ regulatory T cells in humans,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 12, pp. 4793–4798, 2009.

[47] Z. Kaya, C. Leib, and H. A. Katus, “Autoantibodies in heart failure and cardiac dysfunction,” *Circulation Research*, vol. 110, no. 1, pp. 145–158, 2012.

[48] H. Deguchi, Y. Kitaura, T. Hayashi, M. Kotaka, and K. Kawamura, “Cell-mediated immune cardiocyte injury in viral myocarditis of mice and patients,” *Japanese Circulation Journal*, vol. 53, no. 1, pp. 61–77, 1989.

[49] P. Luppi, W. Rudert, A. Licata et al., “Expansion of specific αβ T-cell subsets in the myocardium of patients with myocarditis and idiopathic dilated cardiomyopathy associated with coxsackievirus B infection,” *Human Immunology*, vol. 64, no. 2, pp. 194–210, 2003.

[50] D. L. Fairweather, K. A. Stafford, and Y. K. Sung, “Update on coxsackievirus B3 myocarditis,” *Current Opinion in Rheumatology*, vol. 24, no. 4, pp. 401–407, 2012.

[51] N. Neu, N. R. Rose, K. W. Beisel, A. Herskowitz, G. Gurri-Glass, and S. W. Craig, “Cardiac myosin induces myocarditis in genetically predisposed mice,” *The Journal of Immunology*, vol. 139, no. 11, pp. 3630–3636, 1987.

[52] V. Nindl, R. Maier, D. Ratering et al., “Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy,” *European Journal of Immunology*, vol. 42, no. 9, pp. 2311–2321, 2012.

[53] J. L. Bautista, C. W. J. Lio, S. K. Lathrop et al., “Intracranial competition limits the fate determination of regulatory T cells in the thymus,” *Nature Immunology*, vol. 10, no. 6, pp. 610–617, 2009.

[54] M. Meredith, D. Zemmour, D. Mathis, and C. Benoist, “Aire controls gene expression in the thymic epithelium with ordered stochasticity,” *Nature Immunology*, vol. 16, no. 9, pp. 942–9, 2015.

[55] I. Proekt, C. N. Miller, M. S. Lionakis, and M. S. Anderson, “Insights into immune tolerance from AIRE deficiency,” *Current Opinion in Immunology*, vol. 49, pp. 71–78, 2017.

[56] H. Takaba, Y. Morishita, Y. Tomofuji et al., “Fod2 orches trates a thymic program of self-antigen expression for immune tolerance,” *Cell*, vol. 163, no. 4, pp. 975–987, 2015.

[57] S. C. Smith and P. M. Allen, “Expression of myosin-class II major histocompatibility complexes in the normal myocardium occurs before induction of autoimmune myocarditis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 89, no. 19, pp. 9131–9135, 1992.

[58] D. J. Lenschow, T. L. Walunas, and J. A. Bluestone, “CD8/B7 system of T cell costimulation,” *Annual Review of Immunology*, vol. 14, no. 1, pp. 233–258, 1996.

[59] Y. Xing and K. A. Hogquist, “Chapter: T cell tolerance: central and peripheral,” *Cold Spring Harbor Perspectives in Biology*, vol. 4, no. 6, 2012.

[60] H. C. Probst, K. McCoy, T. Okazaki, T. Honjo, and M. van den Broek, “Resting dendritic cells induce peripheral CD8 T cell tolerance through PD-1 and CTLA-4,” *Nature Immunology*, vol. 6, no. 3, pp. 280–286, 2005.

[61] H. Nishimura, T. Okazaki, Y. Tanaka et al., “Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice,” *Science*, vol. 291, no. 5502, pp. 319–322, 2001.

[62] J. A. Lucas, J. Menke, W. A. Rabacal, F. J. Schoen, A. H. Sharpe, and V. R. Kelley, “Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice,” *The Journal of Immunology*, vol. 181, no. 4, pp. 2513–2521, 2008.

[63] H. Ying, L. Yang, G. Qiao et al., “Cutting edge: CTLA-4–B7 interaction suppresses Th17 cell differentiation,” *The Journal of Immunology*, vol. 185, no. 3, pp. 1375–1378, 2010.

[64] M. L. Tarrio, N. Grabie, D. X. Bu, A. H. Sharpe, and A. H. Lichtman, “PD-1 protects against inflammation and myocardite
damage in T cell-mediated myocarditis,” *The Journal of Immunology*, vol. 188, no. 10, pp. 4876–4884, 2012.

[65] T. Takahashi, Y. Kuniyasu, M. Toda et al., “Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state,” *International Immunology*, vol. 10, no. 12, pp. 1969–1980, 1998.

[66] L. S. Taams, D. B. Palmer, A. N. Akbar, D. S. Robinson, Z. Brown, and C. M. Hawrylycz, “Regulatory T cells in human disease and their potential for therapeutic manipulation,” *Immunology*, vol. 118, no. 1, pp. 1–9, 2006.

[67] C. R. Grant, R. Liberal, G. Mieli-Vergani, D. Vergani, and M. S. Longhi, “Regulatory T-cells in autoimmune diseases: challenges, controversies and—yet—unanswered questions,” *Autoimmunity Reviews*, vol. 14, no. 2, pp. 105–116, 2015.

[68] J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” *Nature Immunology*, vol. 4, no. 4, pp. 330–336, 2003.

[69] S. Sakaguchi, “Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self,” *Nature Immunology*, vol. 6, no. 4, pp. 345–352, 2005.

[70] Y. C. Qiao, Y. H. Pan, W. Ling et al., “The yin and yang of regulatory T cell and therapy progress in autoimmune disease,” *Autoimmunity Reviews*, vol. 16, no. 10, pp. 1058–1070, 2017.

[71] K. Klocke, S. Sakaguchi, R. Holmdahl, and K. Wing, “Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113, no. 17, pp. E2383–E2392, 2016.

[72] M. Afanasyeva, D. Georgakopoulos, and N. R. Rose, “Autoimmune myocarditis: cellular mediators of cardiac dysfunction,” *Autoimmunity Reviews*, vol. 3, no. 7–8, pp. 476–486, 2004.

[73] L. Wei, L. Wei-min, G. Cheng, and Z. Bao-guo, “Upregulation of CD4+CD25+ T lymphocyte by adenosivirus-mediated gene transfer of CTLA4Ig fusion protein in experimental autoimmune myocarditis,” *Autoimmunity*, vol. 39, no. 4, pp. 289–298, 2006.

[74] M. Ono, J. Shimizu, Y. Miyachi, and S. Sakaguchi, “Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein-r,” Foxp3-expressing CD25+ and CD25- regulatory T cells,” *The Journal of Immunology*, vol. 176, no. 8, pp. 4748–4756, 2006.

[75] Y. Shi, M. Fukuoka, G. Li et al., “Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor-β-cossackievirus receptor pathway,” *Circulation*, vol. 121, no. 24, pp. 2624–2634, 2010.

[76] S. A. Huber, A. M. Feldman, and D. Sartini, “Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice,” *Circulation Research*, vol. 99, no. 10, pp. 1109–1116, 2006.

[77] K. Pappritz, K. Savvatis, D. Lindner et al., “Administration of regulatory T cells ameliorates myocardial inflammation in experimental myocarditis,” *European Heart Journal*, vol. 34, suppl 1, pp. P1459–P1459, 2013.

[78] S. A. Huber, “Coxsackievirus B3-induced myocarditis: infection of females during the estrus phase of the ovarian cycle leads to activation of T regulatory cells,” *Virology*, vol. 378, no. 2, pp. 292–298, 2008.

[79] Y. Li, J. S. Heuser, S. D. Kosanke, M. Hemric, and M. W. Cunningham, “Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cells,” *The American Journal of Pathology*, vol. 167, no. 1, pp. 5–15, 2005.

[80] K. Tajiri, S. Sakai, T. Kimura et al., “Endothelin receptor antagonist exacerbates autoimmune myocarditis in mice,” *Life Sciences*, vol. 118, no. 2, pp. 288–296, 2014.

[81] H. Groux, A. O’Garra, M. Bigler et al., “A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis,” *Nature*, vol. 389, no. 6652, pp. 737–742, 1997.

[82] R. de Waal Malefyt, J. Haanen, H. Spits et al., “Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression,” *Journal of Experimental Medicine*, vol. 174, no. 4, pp. 915–924, 1991.

[83] L. Ding, P. S. Linsley, L. Y. Huang, R. N. Germain, and E. M. Shevach, “IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression,” *The Journal of Immunology*, vol. 151, no. 3, pp. 1224–1234, 1993.

[84] N. Misra, J. Bayry, S. Lacroix-Desmazes, M. D. Kazatchkine, and S. V. Kaveri, “Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells,” *The Journal of Immunology*, vol. 172, no. 8, pp. 4676–4680, 2004.

[85] B. An, X. Liu, G. Li, and H. Yuan, “Interleukin-37 ameliorates coxsackievirus B3-induced viral myocarditis by modulating the Th17/regulatory T cell immune response,” *Journal of Cardiovascular Pharmacology*, vol. 69, no. 5, pp. 305–313, 2017.

[86] L. W. Collison, C. J. Workman, T. T. Kuo et al., “The inhibitory cytokine IL-35 contributes to regulatory T-cell function,” *Nature*, vol. 450, no. 7169, pp. 566–569, 2007.

[87] L. W. Collison, V. Chaturvedi, A. L. Henderson et al., “IL-35-mediated induction of a potent regulatory T cell population,” *Nature Immunology*, vol. 11, no. 12, pp. 1093–1101, 2010.

[88] L. Fahlén, S. Read, L. Gorelik et al., “T cells that cannot respond to TGFB-β escape control by CD4+CD25+ regulatory T cells,” *Journal of Experimental Medicine*, vol. 201, no. 5, pp. 737–746, 2005.

[89] M. L. Chen, B. S. Yan, Y. Bando, V. K. Kuchroo, and H. L. Weiner, “Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFB-β-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis,” *The Journal of Immunology*, vol. 180, no. 11, pp. 7327–7337, 2008.

[90] Y. Carrier, J. Yuan, V. K. Kuchroo, and H. L. Weiner, “Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGFB-β T cell transgenic mice,” *The Journal of Immunology*, vol. 178, no. 1, pp. 179–185, 2007.

[91] P. Blyszczuk, B. Müller-Edenborn, T. Valenta et al., “Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis,” *European Heart Journal*, vol. 38, no. 18, pp. ehw116–eh1425, 2017.
[92] X. H. Sun, J. Fu, and D. Q. Sun, "Halofuginone alleviates acute viral myocarditis in suckling BALB/c mice by inhibiting TGF-β1," *Biochemical and Biophysical Research Communications*, vol. 473, no. 2, pp. 558–564, 2016.

[93] T. Wu, Y. Xie, J. Huang et al., "The optimal intervention time of bone marrow mesenchymal stem cells in ameliorating cardiac fibrosis induced by viral myocarditis: a randomized controlled trial in mice," *Stem Cells International*, vol. 2017, Article ID 3258035, 9 pages, 2017.

[94] S. Lv, M. Wu, M. Li et al., "Effect and mechanism of QiShe-YiQi pill on experimental autoimmune myocarditis rats," *Medical Science Monitor*, vol. 22, pp. 752–756, 2016.

[95] H. S. Kuehn, W. Ouyang, B. Lo et al., "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4," *Science*, vol. 345, no. 6204, pp. 1623–1627, 2014.

[96] T. Takahashi, T. Tagami, S. Yamazaki et al., "Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4," *Journal of Experimental Medicine*, vol. 192, no. 2, pp. 303–310, 2000.

[97] O. S. Qureshi, Y. Zheng, K. Nakamura et al., "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4," *Science*, vol. 332, no. 6029, pp. 600–603, 2011.

[98] T. L. Walunas, C. Y. Bakker, and J. A. Bluestone, "CTLA-4 ligation blocks CD82-dependent T cell activation," *Journal of Experimental Medicine*, vol. 183, no. 6, pp. 2541–2550, 1996.

[99] M. F. Krummel and J. P. Allison, "CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells," *Journal of Experimental Medicine*, vol. 183, no. 6, pp. 2533–2540, 1996.

[100] A. M. Thornton and E. M. Shevach, "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production," *Journal of Experimental Medicine*, vol. 188, no. 2, pp. 287–296, 1998.

[101] F. F. de Araújo, R. Corrêa-Oliveira, M. O. C. Rocha et al., "Foxp3-CD25high CD4+ regulatory T cells from indeterminate patients with Chagas disease can suppress the effector cells and cytokines and reveal altered correlations with disease severity," *Immunobiology*, vol. 217, no. 8, pp. 768–777, 2012.

[102] L. G. Nogueira, R. H. B. Santos, A. I. Fiorelli et al., "Myocardial gene expression of T-bet, GATA-3, Ror-γt, Foxp3, and hallmark cytokines in chronic Chagas disease cardiomyopathy: an essentially unopposed Treg1-type response," *Mediators of Inflammation*, vol. 2014, Article ID 914326, 9 pages, 2014.

[103] S. Frisancho-Kiss, J. F. Nyland, S. E. Davis et al., "Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA4 during innate immunity," *The Journal of Immunology*, vol. 176, no. 11, pp. 6411–6415, 2006.

[104] D. C. Gondek, L. F. Lu, S. A. Quezada, S. Sakaguchi, and R. J. Noelle, "Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism," *The Journal of Immunology*, vol. 174, no. 4, pp. 1783–1786, 2005.

[105] Y. Xie, C. Gong, L. Bo et al., "Treg responses are associated with PM2.5-induced exacerbation of viral myocarditis," *Inhalation Toxicology*, vol. 27, no. 6, pp. 281–286, 2015.

[106] T. Veiga-Parga, S. Sehrawat, and B. T. Rouse, "Role of regulatory T cells during virus infection," *Immunological Reviews*, vol. 255, no. 1, pp. 182–196, 2013.

[107] A. P. Papageorgiou, M. Swinnen, D. Vanhoutte et al., "Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T cells," *Cardiovascular Research*, vol. 94, no. 1, pp. 115–124, 2012.

[108] H. Jin and X. Guo, "Valproic acid ameliorates coxsackievirus-B3-induced viral myocarditis by modulating Th17/Treg imbalance," *Virology Journal*, vol. 13, no. 1, p. 168, 2016.

[109] L. Yan, F. Hu, X. Yan et al., "Inhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response," *Journal of Molecular Medicine*, vol. 94, no. 9, pp. 1063–1079, 2016.

[110] J. F. Vasconcelos, B. S. F. Souza, T. F. S. Lins et al., "Administration of granulocyte colony-stimulating factor induces immunomodulation, recruitment of T regulatory cells, reduction of myocarditis and decrease of parasite load in a mouse model of chronic Chagas disease cardiomyopathy," *The FASEB Journal*, vol. 27, no. 12, pp. 4691–4702, 2013.

[111] J. Kotner and R. Tarleton, "Endogenous CD4+CD25+ regulatory T cells have a limited role in the control of *Trypanosoma cruzi* infection in mice," *Infection and Immunity*, vol. 75, no. 2, pp. 861–869, 2007.

[112] M. Noutsias, M. Rohde, K. Göldner et al., "Expression of functional T-cell markers and T-cell receptor VBeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy," *European Journal of Heart Failure*, vol. 13, no. 6, pp. 611–618, 2011.

[113] N. Li, H. B. Santos, A. I. Fiorelli et al., "Myocardial gene expression of T-bet, GATA-3, Ror-γt, Foxp3, and hallmark cytokines in chronic Chagas disease cardiomyopathy: an essentially unopposed Treg1-type response," *Mediators of Inflammation*, vol. 2014, Article ID 914326, 9 pages, 2014.

[114] S. Frisancho-Kiss, J. F. Nyland, S. E. Davis et al., "Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA4 during innate immunity," *The Journal of Immunology*, vol. 176, no. 11, pp. 6411–6415, 2006.

[115] T. R. Pang, J. Yuan, Z.-F. Zhu et al., "The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction," *Clinica Chimica Acta*, vol. 411, no. 23–24, pp. 1963–1968, 2010.

[116] H. Tang, Y. Zhong, Y. Zhu, F. Zhao, X. Cui, and Z. Wang, "Low responder T cell susceptibility to the suppressive function of regulatory T cells in patients with dilated cardiomyopathy," *Heart*, vol. 96, no. 10, pp. 765–771, 2010.

[117] D. Bulut, G. Creutzenberg, and A. Mügge, "The number of regulatory T cells correlates with hemodynamic improvement in patients with inflammatory dilated cardiomyopathy after immunoadsorption therapy," *Scandinavian Journal of Immunology*, vol. 77, no. 1, pp. 54–61, 2013.

[118] T. T. Tang, J. Yuan, Z.-F. Zhu et al., "Regulatory T cells ameliorate cardiac remodeling after myocardial infarction," *Basic Research in Cardiology*, vol. 107, no. 1, p. 232, 2011.

[119] K. Yang, Y. Zhang, C. Xu, X. Li, and D. Li, "miR-101 signaling is crucial for regulatory T cells to suppress macrophage-mediated inflammatory response after acute myocardial infarction," *Immunology and Cell Biology*, vol. 94, no. 3, pp. 274–284, 2016.

[120] N. Okamoto, T. Noma, Y. Ishihara et al., "Prognostic value of circulating regulatory T cells for worsening heart failure in heart failure patients with reduced ejection fraction," *International Heart Journal*, vol. 55, no. 3, pp. 271–277, 2014.

[121] N. Pilat, A. M. Farkas, B. Mahr et al., "T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism model," *The Journal of Heart and Lung Transplantation*, vol. 33, no. 4, pp. 429–437, 2014.
[120] Y. Zhou, A. K. Singh, R. F. Hoyt Jr et al., “Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemic myocardium,” The Journal of Thoracic and Cardiovascular Surgery, vol. 148, no. 3, pp. 1131–1137, 2014.

[121] J. G. Barin and D. Čiháková, “Control of inflammatory heart disease by CD4+ T cells,” Annals of the New York Academy of Sciences, vol. 1285, no. 1, pp. 80–96, 2013.

[122] J. Yuan, M. Yu, Q. W. Lin et al., “Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis,” The Journal of Immunology, vol. 185, no. 7, pp. 4004–4010, 2010.

[123] G. Vahedi, A. C. Poholek, T. W. Hand et al., “Th17 cell identity and evolution of differential transcriptomes and epigenomes,” Immunological Reviews, vol. 252, no. 1, pp. 24–40, 2013.

[124] M. Shi, C. A. Cox, B. P. Vistica, C. Tan, E. F. Wawrousek, and I. Gery, “Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells,” Journal of Immunology, vol. 181, no. 10, pp. 7205–7213, 2008.

[125] K. Hirota, J. H. Duarte, M. Veldhoen et al., “Fate mapping of IL-17-producing T cells in inflammatory responses,” Nature Immunology, vol. 12, no. 3, pp. 255–263, 2011.

[126] K. Boniface, W. M. Blumenschein, K. Brevont-Porth et al., “Human Th17 cells comprise heterogeneous subsets including IFN-γ-producing cells with distinct properties from the Th1 lineage,” The Journal of Immunology, vol. 185, no. 1, pp. 679–687, 2010.

[127] U. Eriksson, M. O. Kurre, W. Sebold, F. Brombacher, and M. Kopf, “Dual role of the IL-12/IFN-γ axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-γ,” The Journal of Immunology, vol. 167, no. 9, pp. 5464–9, 2001.

[128] U. Eriksson, M. O. Kurre, R. Bingisser et al., “Lethal autoimmune myocarditis in interferon-γ receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction,” Circulation, vol. 103, no. 1, pp. 18–21, 2001.

[129] A. Valaperti, R. R. Marty, G. Kania et al., “CD11b+ monocytes abrogate Th17 CD4+ T cell-mediated experimental autoimmune myocarditis,” The Journal of Immunology, vol. 180, no. 4, pp. 2686–2695, 2008.

[130] A. Valaperti, M. Nishii, D. Germano, P. P. Liu, and U. Eriksson, “Vaccination with Flt3L-induced CD8α dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis,” Vaccine, vol. 31, no. 42, pp. 4802–4811, 2013.

[131] M. A风扇asyeva, D. Georgakopoulos, D. F. Belardi et al., “Impaired up-regulation of CD25 on CD4+ T cells in IFN-γ knockout mice is associated with progression of myocarditis to heart failure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 1, pp. 180–185, 2005.

[132] M. K. McCarthy, M. C. Procario, N. Twisselmann et al., “Proinflammatory effects of interferon gamma in mouse adenovirus 1 myocarditis,” Journal of Virology, vol. 89, no. 1, pp. 468–479, 2015.

[133] C. G. Martinez, D. Zamith-Miranda, M. G. da Silva et al., “P2x7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M1 receptors: autoantibody levels, heart functionality and cytokine expression,” Scientific Reports, vol. 5, no. 1, 2015.